{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:58:27Z","timestamp":1787979507505,"version":"build-2784847793"},"reference-count":62,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The International Staging Evaluation and Response Criteria Harmonization for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL) seeks to provide an appropriate, universal differentiation between E-lesions and stage IV extranodal disease in Hodgkin lymphoma (HL). A literature search was performed through the PubMed and Google Scholar databases using the terms \u201cHodgkin disease,\u201d and \u201cextranodal,\u201d \u201cextralymphatic,\u201d \u201cE lesions,\u201d \u201cE stage,\u201d or \u201cE disease.\u201d Publications were reviewed for the number of participants; median age and age range; diagnostic modalities used for staging; and the definition, incidence, and prognostic significance of E-lesions. Thirty-six articles describing 12\u2009640 patients met the inclusion criteria. Most articles reported staging per the Ann Arbor (72%, 26\/36) or Cotswolds modification of the Ann Arbor staging criteria (25%, 9\/36), and articles rarely defined E-lesions or disambiguated \u201cextranodal disease.\u201d The overall incidence of E-lesions for patients with stage I-III HL was 11.5% (1330\/11\u2009602 unique patients). Available stage-specific incidence analysis of 3888 patients showed a similar incidence of E-lesions in stage II (21.2%) and stage III (21.9%), with E-lesions rarely seen with stage I disease (1.1%). E-lesions likely remain predictive, but we cannot unequivocally conclude that identifying E-lesions in HL imparts prognostic value in the modern era of the more selective use of targeted radiation therapy. A harmonized E-lesion definition was reached based on the available evidence and the consensus of the SEARCH working group. We recommend that this definition of E-lesion be applied in future clinical trials with explicit reporting to confirm the prognostic value of E-lesions.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010024","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T13:10:42Z","timestamp":1690809042000},"page":"6303-6319","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Significance of E-lesions in Hodgkin lymphoma and the creation of a new consensus definition: a report from SEARCH"],"prefix":"10.1182","volume":"7","author":[{"given":"Eline A. M.","family":"Zijtregtop","sequence":"first","affiliation":[{"name":"1Department of Pediatric Oncology\/Hematology, Erasmus MC-Sophia Children\u2019s Hospital, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Zeal","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, University of Tennessee Health Sciences Center, Memphis, TN"},{"name":"3Department of Medicine, University of Tennessee Health Sciences Center, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika L.","family":"Metzger","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, University of Tennessee Health Sciences Center, Memphis, TN"},{"name":"4Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara M.","family":"Kelly","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics, Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mauz-Koerholz","sequence":"additional","affiliation":[{"name":"6Department of P\u00e4diatrische H\u00e4matologie und Onkologie, Zentrum f\u00fcr Kinderheilkunde der Justus-Liebig-Universit\u00e4t Giessen, Giessen, Germany"},{"name":"7Medical Faculty, Martin-Luther-University of Halle-Wittenberg, Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2092-2219","authenticated-orcid":false,"given":"Stephan D.","family":"Voss","sequence":"additional","affiliation":[{"name":"8Department of Radiology, Boston Children\u2019s Hospital Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2580-4171","authenticated-orcid":false,"given":"Kathleen","family":"McCarten","sequence":"additional","affiliation":[{"name":"9Imaging and Radiation Oncology Core-Rhode Island, Lincoln, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4182-9355","authenticated-orcid":false,"given":"Jamie E.","family":"Flerlage","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, University of Tennessee Health Sciences Center, Memphis, TN"},{"name":"4Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6482-1823","authenticated-orcid":false,"given":"Auke","family":"Beishuizen","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology\/Hematology, Erasmus MC-Sophia Children\u2019s Hospital, Rotterdam, The Netherlands"},{"name":"10Department of Hemato-Oncology, Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"issue":"10","key":"2023102313410192600_bib1","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2008-10-184143","article-title":"A\u00a0risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425","volume":"114","author":"Schwartz","year":"2009","journal-title":"Blood"},{"issue":"23","key":"2023102313410192600_bib2","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.2009.26.9381","article-title":"Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study","volume":"28","author":"Mauz-Korholz","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2023102313410192600_bib3","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1200\/JCO.2014.59.4853","article-title":"Pediatric Hodgkin lymphoma","volume":"33","author":"Mauz-Korholz","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023102313410192600_bib4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cncr.30979","article-title":"Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: an adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis","volume":"124","author":"Henderson","year":"2018","journal-title":"Cancer"},{"issue":"4","key":"2023102313410192600_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 16","key":"2023102313410192600_bib6","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2022.40.16_suppl.7503","article-title":"First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III\/IV classical Hodgkin lymphoma: an updated analysis of ECHELON-1","volume":"40","author":"Ansell","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6_Part_1","key":"2023102313410192600_bib7","first-page":"1310","article-title":"Report of the committee on the staging of Hodgkin's disease","volume":"26","author":"Rosenberg","year":"1966","journal-title":"Cancer Res"},{"issue":"11","key":"2023102313410192600_bib8","first-page":"1814","article-title":"Prognostic and therapeutic implications of staging in extranodal Hodgkin's disease","volume":"31","author":"Musshoff","year":"1971","journal-title":"Cancer Res"},{"issue":"11","key":"2023102313410192600_bib9","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"issue":"11","key":"2023102313410192600_bib10","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023102313410192600_bib11","first-page":"1862","article-title":"Report of the committee on Hodgkin's disease staging procedures","volume":"31","author":"Rosenberg","year":"1971","journal-title":"Cancer Res"},{"issue":"2","key":"2023102313410192600_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0009-9260(82)80038-X","article-title":"The response to treatment of nodular sclerosing Hodgkin's disease with extranodal involvement","volume":"33","author":"Hudson","year":"1982","journal-title":"Clin Radiol"},{"issue":"12","key":"2023102313410192600_bib13","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1200\/JCO.1984.2.12.1421","article-title":"Is it an E lesion or stage IV? An unsettled issue in Hodgkin's disease staging","volume":"2","author":"Connors","year":"1984","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2023102313410192600_bib14","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023102313410192600_bib15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0167-8140(01)00456-X","article-title":"Up-front centralized data review and individualized treatment proposals in a multicenter pediatric Hodgkin's disease trial with 71 participating hospitals: the experience of the German-Austrian pediatric multicenter trial DAL-HD-90","volume":"62","author":"Dieckmann","year":"2002","journal-title":"Radiother Oncol"},{"issue":"4","key":"2023102313410192600_bib16","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.ijrobp.2003.08.033","article-title":"Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group","volume":"58","author":"Eich","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"2023102313410192600_bib17","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(17)30696-4","article-title":"Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group","volume":"18","author":"Eichenauer","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"2023102313410192600_bib18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1023\/A:1008325627670","article-title":"Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin Lymphoma Study Group","volume":"11","author":"Franklin","year":"2000","journal-title":"Ann Oncol"},{"issue":"1","key":"2023102313410192600_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(21)00470-8","article-title":"Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial","volume":"23","author":"Mauz-Korholz","year":"2022","journal-title":"Lancet Oncology"},{"key":"2023102313410192600_bib20","unstructured":"National Institutes of Health, US National Library of Medicine\n          . Second international inter-group study for classical Hodgkin lymphoma in children and adolescents. 2016. Accessed 15 September 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02684708."},{"key":"2023102313410192600_bib21","doi-asserted-by":"crossref","first-page":"e26421","DOI":"10.1002\/pbc.26421","article-title":"Staging evaluation and response criteria harmonization (SEARCH) for childhood, adolescent and young adult Hodgkin lymphoma (CAYAHL): methodology statement","volume":"64","author":"Flerlage","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"9-10","key":"2023102313410192600_bib22","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0360-3016(77)90183-3","article-title":"Patterns of relapse in stages I, II and IIIA Hodgkin's disease: influence of initial therapy and implications for the future","volume":"2","author":"Levi","year":"1977","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2023102313410192600_bib23","first-page":"711","article-title":"Hodgkin's disease with direct extension into pulmonary parenchyma from a mediastinal mass: a presentation requiring special therapeutic considerations","volume":"66","author":"Wiernik","year":"1982","journal-title":"Cancer Treat Rep"},{"issue":"3","key":"2023102313410192600_bib24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0002-9343(77)90274-1","article-title":"Limited extranodal Hodgkin's disease. unfavorable prognosis and therapeutic implications","volume":"63","author":"Levi","year":"1977","journal-title":"Am J Med"},{"issue":"3","key":"2023102313410192600_bib25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/blood.V59.3.455.455","article-title":"The management of stage I--II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience","volume":"59","author":"Hoppe","year":"1982","journal-title":"Blood"},{"issue":"4","key":"2023102313410192600_bib26","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1200\/JCO.1986.4.4.472","article-title":"Stage IIB Hodgkin's disease: the Stanford experience","volume":"4","author":"Crnkovich","year":"1986","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023102313410192600_bib27","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1200\/JCO.1997.15.6.2275","article-title":"Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease","volume":"15","author":"Loeffler","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"2023102313410192600_bib28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/978-3-642-83781-4_15","article-title":"Risk factor adapted treatment of Hodgkin's lymphoma: strategies and perspectives","volume":"117","author":"Loeffler","year":"1989","journal-title":"Recent Results Cancer Res"},{"issue":"2","key":"2023102313410192600_bib29","first-page":"476","article-title":"Rapidly alternating COPP\/ABV\/IMEP is not superior to conventional alternating COPP\/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5","volume":"20","author":"Sieber","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023102313410192600_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(21)00470-8","article-title":"Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial","volume":"23","author":"Mauz-Korholz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"2023102313410192600_bib31","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1470-2045(23)00019-0","article-title":"Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study","volume":"24","author":"Mauz-Korholz","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10","key":"2023102313410192600_bib32","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1200\/JCO.1992.10.10.1602","article-title":"Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology","volume":"10","author":"Oberlin","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023102313410192600_bib33","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0360-3016(01)01798-9","article-title":"Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial","volume":"51","author":"Ruhl","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2023102313410192600_bib34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JCO.1985.3.2.207","article-title":"Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease","volume":"3","author":"Zittoun","year":"1985","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 9","key":"2023102313410192600_bib35","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1002\/1097-0142(19850501)55:9+<2072::AID-CNCR2820551407>3.0.CO;2-K","article-title":"Stage IA to IIB supradiaphragmatic Hodgkin\u2019s disease. Long-term survival and relapse frequency","volume":"55","author":"Leslie","year":"1985","journal-title":"Cancer"},{"issue":"8","key":"2023102313410192600_bib36","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.1989.7.8.1059","article-title":"Stage IA-IIB Hodgkin's disease: staging and treatment of patients with large mediastinal adenopathy","volume":"7","author":"Leopold","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023102313410192600_bib37","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0360-3016(99)00052-8","article-title":"Long-term follow-up of patients treated with primary radiotherapy for supradiaphragmatic Hodgkin's disease at St. Jude Children's Research Hospital","volume":"44","author":"Shah","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2023102313410192600_bib38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1034\/j.1600-0609.2003.00108.x","article-title":"Bulky disease is the most important prognostic factor in Hodgkin lymphoma stage IIB","volume":"71","author":"Glimelius","year":"2003","journal-title":"Eur J Haematol"},{"issue":"5","key":"2023102313410192600_bib39","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0360-3016(03)00765-X","article-title":"Impact of chest wall and lung invasion on outcome of stage I-II Hodgkin's lymphoma after combined modality therapy","volume":"57","author":"Hodgson","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"22","key":"2023102313410192600_bib40","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2004.02.139","article-title":"Risk-adapted, combined-modality therapy with VAMP\/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease","volume":"22","author":"Hudson","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023102313410192600_bib41","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ijrobp.2003.11.029","article-title":"Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma","volume":"59","author":"Vassilakopoulos","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"66","key":"2023102313410192600_bib42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1600-0609.2005.00463.x","article-title":"How to define intermediate stage in Hodgkin's lymphoma?","volume":"75","author":"Gisselbrecht","year":"2005","journal-title":"Eur J Haematol"},{"issue":"24","key":"2023102313410192600_bib43","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2023102313410192600_bib44","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.3109\/10428194.2013.871631","article-title":"Radiation therapy for early stage unfavorable Hodgkin lymphoma: is dose reduction feasible?","volume":"55","author":"Laskar","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2023102313410192600_bib45","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/j.clml.2018.04.001","article-title":"Extralymphatic disease is an independent prognostic factor in Hodgkin lymphoma","volume":"18","author":"Gaudio","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2023102313410192600_bib46","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000490489","article-title":"Bone involvement in Hodgkin's lymphoma: clinical features and outcome","volume":"140","author":"Gaudio","year":"2018","journal-title":"Acta Haematol"},{"issue":"2","key":"2023102313410192600_bib47","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"2023102313410192600_bib48","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3109\/10428194.2010.547155","article-title":"Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group\/Trans-Tasman Radiation Oncology Group","volume":"52","author":"Wirth","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2023102313410192600_bib49","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/hon.1024","article-title":"Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy","volume":"30","author":"Gobbi","year":"2012","journal-title":"Hematol Oncol"},{"issue":"12","key":"2023102313410192600_bib50","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/cas.12282","article-title":"Metabolic tumor volume by positron emission tomography\/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma","volume":"104","author":"Song","year":"2013","journal-title":"Cancer Sci"},{"issue":"1","key":"2023102313410192600_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.hemonc.2019.08.009","article-title":"Ten-year survival outcomes for patients with early stage classical Hodgkin lymphoma: an analysis from Kentucky Cancer Registry","volume":"13","author":"Myint","year":"2020","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"6","key":"2023102313410192600_bib52","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s00277-021-04537-5","article-title":"PET\/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET\/CT in a prospective trial","volume":"100","author":"Picardi","year":"2021","journal-title":"Ann Hematol"},{"issue":"20","key":"2023102313410192600_bib53","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.21.00108","article-title":"Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma","volume":"39","author":"Kumar","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023102313410192600_bib54","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"2023102313410192600_bib55","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/1097-0142(197712)40:6<2896::AID-CNCR2820400620>3.0.CO;2-S","article-title":"Extended field radiation therapy in Hodgkin's disease: analysis of failures","volume":"40","author":"Mill","year":"1977","journal-title":"Cancer"},{"issue":"4","key":"2023102313410192600_bib56","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/1097-0142(19850815)56:4<864::AID-CNCR2820560427>3.0.CO;2-P","article-title":"Laparotomy-staged IA versus IIA Hodgkin's disease. A comparative study with evaluation of prognostic factors for stage IIA disease","volume":"56","author":"Zagars","year":"1985","journal-title":"Cancer"},{"issue":"3","key":"2023102313410192600_bib57","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00004728-198006000-00014","article-title":"The role of computed tomography in the initial staging and subsequent management of the lymphomas","volume":"4","author":"Ellert","year":"1980","journal-title":"J\u00a0Comput Assist Tomogr"},{"issue":"4","key":"2023102313410192600_bib58","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2214\/ajr.143.4.719","article-title":"CT evaluation of cardiophrenic angle lymph nodes in patients with malignant lymphoma","volume":"143","author":"Cho","year":"1984","journal-title":"AJR Am J Roentgenol"},{"issue":"9","key":"2023102313410192600_bib59","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/1097-0142(19850501)55:9<1892::AID-CNCR2820550909>3.0.CO;2-B","article-title":"Computerized tomography evaluation of chest wall involvement in lymphoma","volume":"55","author":"Cho","year":"1985","journal-title":"Cancer"},{"issue":"1","key":"2023102313410192600_bib60","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1148\/radiology.169.1.3420256","article-title":"Hodgkin disease: clinical utility of CT in initial staging and treatment","volume":"169","author":"Hopper","year":"1988","journal-title":"Radiology"},{"issue":"1","key":"2023102313410192600_bib61","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1148\/radiographics.21.1.g01ja02161","article-title":"Extranodal Hodgkin disease: spectrum of disease","volume":"21","author":"Guermazi","year":"2001","journal-title":"Radiographics"},{"issue":"1","key":"2023102313410192600_bib62","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00330-018-5445-8","article-title":"Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin's lymphoma: a comparison with multi-modality reference standard including (18)F-FDG-PET-CT","volume":"29","author":"Latifoltojar","year":"2019","journal-title":"Eur Radiol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/20\/6303\/2085120\/blooda_adv-2023-010024-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/20\/6303\/2085120\/blooda_adv-2023-010024-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T13:41:36Z","timestamp":1698068496000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/20\/6303\/497200\/Significance-of-E-lesions-in-Hodgkin-lymphoma-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":62,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023,10,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010024","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]}}}